Page 3 - Inaugural Issue News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inaugural issue. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inaugural Issue Today - Breaking & Trending Today

Several GOP Senators Consider Blocking Election Certification – American Free Press


By Mark Anderson
According to a post on the website of the Republic Broadcasting Network (RBN), Republican Senator-elect Tommy Tuberville of Alabama “may join efforts to block the Electoral College vote from being certified” when the customary joint session of Congress is seated Jan. 6 to finalize the Electoral College vote for president.
This announcement comes amid efforts in Arizona and most or all of the other most-disputed states in the hotly contested Nov. 3 general election to designate an alternative slate of electors in favor of President Donald Trump, due to the total lack of confidence in the integrity of the election. ....

United States , Lou Dobbs , Donald Trump , Rand Paul , Ted Cruz , Mark Anderson , Tommy Tuberville , Joe Biden , Republic Broadcasting Network , Senate Majority Leader Mitch Mcconnellr Ky , Electoral College , A Journal Of Deep Political Historical Research , Republican Senator Elect Tommy Tuberville , President Donald Trump , Arizona Republic , Save America , Republican House , Senate Majority Leader Mitch Mcconnell , House Speaker Nancy Pelosi , Democrat Joe Biden , Texas Ground , Deep Political , Historical Research , Inaugural Issue , President Trump , Truth Journal Inaugural ,

Innovent Announces NMPA Granted New Indication Approvals for SULINNO® (Adalimumab Injection) for the


Search jobs
23-Dec-2020
Innovent Announces NMPA Granted New Indication Approvals for SULINNO® (Adalimumab Injection) for the Treatment of Pediatric Plaque Psoriasis and Non-infectious Uveitis
SAN FRANCISCO and SUZHOU, China, Dec. 23, 2020 /PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces that SULINNO® (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration (NMPA) of China for two new indications, including the treatment of pediatric plaque psoriasis and non-infectious intermediate uveitis, posterior uveitis and panuveitis in adults who do not respond adequately to corticosteroids, require restraint of cor ....

United States , Hong Kong , Innovent Biologics , Adimab Incyte , Eli Lilly , Prnewswire Innovent Biologics Inc , National Medical Products Administration , Md Anderson Cancer Center , North America , Inaugural Issue , Lancet Rheumatology , Qian Lei , Senior Director , Medical Sciences , Special Diseases , Pediatric Plaque , Non Infectious Uveitis , Main Board , Stock Exchange , Hong Kong Limited , Cancer Center , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் , எலி லில்லி , ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , வடக்கு அமெரிக்கா ,

Innovent Announces NMPA Granted New Indication Approvals for SULINNO® (Adalimumab Injection) for the Treatment of Pediatric Plaque Psoriasis and Non-infectious Uveitis


Search jobs
23-Dec-2020
Innovent Announces NMPA Granted New Indication Approvals for SULINNO® (Adalimumab Injection) for the Treatment of Pediatric Plaque Psoriasis and Non-infectious Uveitis
SAN FRANCISCO and SUZHOU, China, Dec. 22, 2020 /PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces that SULINNO® (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration (NMPA) of China for two new indications, including the treatment of pediatric plaque psoriasis and non-infectious intermediate uveitis, posterior uveitis and panuveitis in adults who do not respond adequately to corticosteroids, require restraint of cor ....

United States , Hong Kong , Innovent Biologics , Adimab Incyte , Eli Lilly , Prnewswire Innovent Biologics Inc , National Medical Products Administration , Md Anderson Cancer Center , North America , Inaugural Issue , Lancet Rheumatology , Qian Lei , Senior Director , Medical Sciences , Special Diseases , Pediatric Plaque , Non Infectious Uveitis , Main Board , Stock Exchange , Hong Kong Limited , Cancer Center , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் , எலி லில்லி , ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , வடக்கு அமெரிக்கா ,